For those who think when TG is high, TG (instead of apoB) or even LDL-C is the goal of therapy, this review is so important. Time for apoB to be what lipid & ASCVD guidelines are focused on. National Lipid Association European Atherosclerosis Society European Society of Cardiology https://lnkd.in/eJhduBFF
Thomas Dayspring, MD FACP, FNLA’s Post
More Relevant Posts
-
ApoB has been the standard for many years. However, it hasn't even scratched the surface in clinical workflows. I suspect it will be another decade before it will be the standard of care. The reasons for this is that many medical groups are still using pre-printed (paper) for ordering labs, EHR order sets haven't been updated, patients still rely on outdated HDL and TG data, and reimbursement packages don't mention apoB and Lp(a). Lipidology isn't the only field in healthcare affected by entrenchment. This is health literacy. Not a curse word, but a patient empowerment tool.
For those who think when TG is high, TG (instead of apoB) or even LDL-C is the goal of therapy, this review is so important. Time for apoB to be what lipid & ASCVD guidelines are focused on. National Lipid Association European Atherosclerosis Society European Society of Cardiology https://lnkd.in/eJhduBFF
-
-
Most viewed in the last 7 days from JAMA Cardiology: The beneficial impact of clopidogrel monotherapy over aspirin monotherapy was consistent for patients who experienced percutaneous coronary intervention and were event-free during 6 to 18 months of dual antiplatelet therapy. https://ja.ma/4gmoGgD
-
-
Most viewed in the last 7 days from JAMA Cardiology: The beneficial impact of clopidogrel monotherapy over aspirin monotherapy was consistent for patients who experienced percutaneous coronary intervention and were event-free during 6 to 18 months of dual antiplatelet therapy. https://ja.ma/49rxMqr
-
-
Overcoming Lipid Rx inertia - sooner the better to get ASCVD patients to goal (sadly now - few achieve that with initial therapy)- start a PCSK9i rapidly (this study with inclisiran) - Great editorial by Michael Shapiro & Charles German https://lnkd.in/eY6RxSVw The study is at https://lnkd.in/ewJqt9mW National Lipid Association European Atherosclerosis Society European Society of Cardiology
-
-
Ambassador for Africa in ISfTeH- Author of Tips and Tricks in Cardiology, ECG, Echo books- MedShr Clinical Leader
We hear a lot about a famous drug in the treatment of Dyslipidemia, which is known as PCSK9 inhibitors, but many people do not know how it works? Find the answer in an easy and simple way in my book "Tips and Tricks in Cardiology "
-
-
Most viewed in the last 7 days from JAMA Cardiology: In patients with ACS undergoing percutaneous coronary intervention with drug-eluting stents, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE. https://ja.ma/3ZIKU61
-
-
Ambassador for Africa in ISfTeH- Author of Tips and Tricks in Cardiology, ECG, Echo books- MedShr Clinical Leader
How to manage patients with CKD and Venous thromboembolism (DVT or pulmonary embolism)? Check the ideal answer from my book "Tips and Tricks in Cardiology " Contact me if you are interested in getting a copy
-
-
Most viewed in the last 7 days from JAMA Cardiology: Are ticagrelor or clopidogrel monotherapy after PCI and 1 to 3 month DAPT similarly effective and safer compared with standard DAPT? https://ja.ma/4aCIxWd
-
-
Most viewed in the last 7 days from JAMA Cardiology: In patients with ACS undergoing percutaneous coronary intervention with drug-eluting stents, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE. https://ja.ma/4iNmbpD
-
-
A revolutionary new perception on anticoagulation treatment in patients with ACS undergoing PCI with DES. New insights that will most probably impact the upcoming guidelines
Most viewed in the last 7 days from JAMA Cardiology: In patients with ACS undergoing percutaneous coronary intervention with drug-eluting stents, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE. https://ja.ma/4iNmbpD
-
Associate Physician, Brigham and Women's Hospital | Group Director Clinical R and D at AstraZeneca
6moI saw the article about apoB v non-HDL-c v LDL-c. I still don’t see the incremental value of apoB v non-HDL-c for clinical decision makiing. The later is right there before your eyes and if it’s not there, just do the subtaction since the total cholesterol and HDL-C will be there. No need to send out a specimen for apoB analysis.